Cargando…

COVID-19 et maladies bulleuses auto-immunes en 2022

The COVID-19 pandemic is evolving daily, forcing health authorities and physicians to continuously adapt. Patients with autoimmune bullous diseases (ABD), who are often elderly and/or immunocompromised, constitute a population at very high risk of developing a severe form. This study on the impact o...

Descripción completa

Detalles Bibliográficos
Autor principal: Hébert, V.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Masson SAS. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8847086/
http://dx.doi.org/10.1016/j.fander.2022.02.001
_version_ 1784651973280137216
author Hébert, V.
author_facet Hébert, V.
author_sort Hébert, V.
collection PubMed
description The COVID-19 pandemic is evolving daily, forcing health authorities and physicians to continuously adapt. Patients with autoimmune bullous diseases (ABD), who are often elderly and/or immunocompromised, constitute a population at very high risk of developing a severe form. This study on the impact of COVID-19 on patients with ABD has brought out several key messages: (i) the prescription of rituximab is associated with an increased risk of mortality, contrary to conventional immunosuppressants; (ii) rituximab should only be prescribed for patients in flare-up of their disease, in the absence of any therapeutic alternative; (iii) vaccination of patients and their entourage is still the best solution for reducing the risk of progression to a severe form.
format Online
Article
Text
id pubmed-8847086
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Elsevier Masson SAS.
record_format MEDLINE/PubMed
spelling pubmed-88470862022-02-16 COVID-19 et maladies bulleuses auto-immunes en 2022 Hébert, V. Annales de Dermatologie et de Vénéréologie - FMC Mise Au Point The COVID-19 pandemic is evolving daily, forcing health authorities and physicians to continuously adapt. Patients with autoimmune bullous diseases (ABD), who are often elderly and/or immunocompromised, constitute a population at very high risk of developing a severe form. This study on the impact of COVID-19 on patients with ABD has brought out several key messages: (i) the prescription of rituximab is associated with an increased risk of mortality, contrary to conventional immunosuppressants; (ii) rituximab should only be prescribed for patients in flare-up of their disease, in the absence of any therapeutic alternative; (iii) vaccination of patients and their entourage is still the best solution for reducing the risk of progression to a severe form. Elsevier Masson SAS. 2022-04 2022-02-16 /pmc/articles/PMC8847086/ http://dx.doi.org/10.1016/j.fander.2022.02.001 Text en © 2022 Elsevier Masson SAS. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Mise Au Point
Hébert, V.
COVID-19 et maladies bulleuses auto-immunes en 2022
title COVID-19 et maladies bulleuses auto-immunes en 2022
title_full COVID-19 et maladies bulleuses auto-immunes en 2022
title_fullStr COVID-19 et maladies bulleuses auto-immunes en 2022
title_full_unstemmed COVID-19 et maladies bulleuses auto-immunes en 2022
title_short COVID-19 et maladies bulleuses auto-immunes en 2022
title_sort covid-19 et maladies bulleuses auto-immunes en 2022
topic Mise Au Point
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8847086/
http://dx.doi.org/10.1016/j.fander.2022.02.001
work_keys_str_mv AT hebertv covid19etmaladiesbulleusesautoimmunesen2022